Cos J, Bellmunt J, Soler C, Ribas A, Lluis JM, Murio JE, Margarit C
Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line. Cancer Invest. 2000; 18(5):429-35.
Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line.
Pal SK, Hoffman-Censits J, Zheng H, Kaiser C, Tayama D, Bellmunt J
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. Eur Urol. 2018 05; 73(5):800-806.
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW, Ding B, Kaiser C, Fassò M, O'Hear C, Vogelzang NJ
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study. JAMA Oncol. 2018 Apr 01; 4(4):537-544.
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
Avelumab for the treatment of urothelial cancer. Expert Rev Anticancer Ther. 2018 05; 18(5):421-429.
Avelumab for the treatment of urothelial cancer.
Angelergues A, Efstathiou E, Gyftaki R, Wysocki PJ, Lainez N, Gonzalez I, Castellano DE, Ozguroglu M, Carbonero IG, Flechon A, Borrega P, Guillot A, Balea BC, Le Moulec S, Esteban E, Munarriz J, Rubio G, Birtle AJ, Delanoy N, Bellmunt J, Oudard S
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents. Clin Genitourin Cancer. 2018 08; 16(4):e777-e784.
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.
The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int. 2009 Mar; 103(5):572-7.
The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations.
Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin DF, de Wit R
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. J Clin Oncol. 2018 06 01; 36(16):1579-1587.
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.
Vicente P, Bellmunt J, Ruiz-Marcellan C, García A, Rovirosa A, Solé LA
[Primary non-Hodgkin's lymphoma of the breast]. Med Clin (Barc). 1993 Sep 11; 101(7):261-3.
[Primary non-Hodgkin's lymphoma of the breast].
Albanell J, Bellmunt J, Molina R, García M, Caragol I, Bermejo B, Ribas A, Carulla J, Gallego OS, Español T, Solé Calvo LA
Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis. Anticancer Res. 1996 Mar-Apr; 16(2):1027-32.
Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis.
Ribas A, Bellmunt J, Albanell J, De Torres I, Bermejo B, De Torres JA, Morote J, Gallardo E, Vera R, Carulla J, Sole-Calvo LA
Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI). Tumori. 1996 Nov-Dec; 82(6):554-9.
Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI).
Solé LA, Albanell J, Bellmunt J, Ribas A, Gallego OS, Carulla J
Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. Cancer. 1995 Feb 01; 75(3):831-5.
Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer.
Editorial comment on: Vaccine therapy in patients with renal cell carcinoma. Eur Urol. 2009 Jun; 55(6):1342-3.
Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
Sonpavde G, Pond GR, Rosenberg JE, Choueiri TK, Bellmunt J, Regazzi AM, Mullane SA, Necchi A, Raggi D, Lee JL, Lee S, Simpson J, Derleth CL, Lin SW, Bajorin DF
Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clin Genitourin Cancer. 2018 08; 16(4):e961-e967.
Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.
Bellmunt J, Morales S, Allende E, Solé Calvo LA
[Epithelioid hemangioendothelioma of the liver]. Med Clin (Barc). 1990 Feb 10; 94(5):198.
[Epithelioid hemangioendothelioma of the liver].
Navarro M, Morales S, Bellmunt J, Jolis L
[Metachronic squamous carcinoma of the tonsils to microcytic carcinoma of the esophagus]. Med Clin (Barc). 1990 Jan 20; 94(2):77-8.
[Metachronic squamous carcinoma of the tonsils to microcytic carcinoma of the esophagus].
Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, Sherif A, von der Maase H, Tsukamoto T, Soloway MS
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007 Jan; 69(1 Suppl):62-79.
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.
Bellmunt J, González-Larriba JL, Climent MA, López-Vivanco G, Urruticoechea L, Albanell J
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Sorafenib TARGET trial results in Spanish patients. Clin Transl Oncol. 2007 Oct; 9(10):671-3.
Sorafenib TARGET trial results in Spanish patients.
Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). Br J Cancer. 2018 05; 118(11):1434-1441.
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).
Laes JF, Aftimos P, Barthelemy P, Bellmunt J, Berchem G, Camps C, Peñas RL, Finzel A, García-Foncillas J, Hervonen P, Wahid I, Joensuu T, Kathan L, Kong A, Mackay J, Mikropoulos C, Mokbel K, Mouysset JL, Odarchenko S, Perren TJ, Pienaar R, Regonesi C, Alkhayyat SS, El Kinge AR, Abulkhair O, Galal KM, Ghanem H, El Karak F, Garcia A, Ghitti G, Sadik H
The clinical impact of using complex molecular profiling strategies in routine oncology practice. Oncotarget. 2018 Apr 17; 9(29):20282-20293.
The clinical impact of using complex molecular profiling strategies in routine oncology practice.
Palou J, Banus JM, Bellmunt J, Carulla J, Egido R
Wilms' tumor in an adult patient. Urol Int. 1988; 43(6):349-51.
McKay RR, Bossé D, Gray KP, Michaelson MD, Krajewski K, Jacene HA, Walsh M, Bellmunt J, Pomerantz M, Harshman LC, Choueiri TK
Clinical cancer research : an official journal of the American Association for Cancer Research
Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clin Cancer Res. 2018 09 01; 24(17):4081-4088.
Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases.
Wagner M, Bellmunt J, Boutros C, Bonardel G, Loriot Y, Albiges L, Massard C, Fizazi K
False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses. Clin Genitourin Cancer. 2013 Mar; 11(1):66-9.
False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses.
Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, Bouvier N, Mullane SA, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Berger MF, Bajorin DF, Bellmunt J, Iyer G, Rosenberg JE
Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma." Urol Oncol. 2018 07; 36(7):345-346.
Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."
Shi H, Yu H, Bellmunt J, Leow JJ, Chen X, Guo C, Yang H, Zhang X
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis. Qual Life Res. 2018 Nov; 27(11):2759-2775.
Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis.
Kanesvaran R, Le Saux O, Motzer R, Choueiri TK, Scotté F, Bellmunt J, Launay-Vacher V
Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. Lancet Oncol. 2018 06; 19(6):e317-e326.
Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology.
Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther. 2010 Jun; 10(6):825-35.
Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 2013 Apr; 63(4):717-23.
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
Li Q, Damish AW, Frazier Z, Liu D, Reznichenko E, Kamburov A, Bell A, Zhao H, Jordan EJ, Gao SP, Ma J, Abbosh PH, Bellmunt J, Plimack ER, Lazaro JB, Solit DB, Bajorin D, Rosenberg JE, D'Andrea AD, Riaz N, Van Allen EM, Iyer G, Mouw KW
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2019 02 01; 25(3):977-988.
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011 Jan; 59(1):61-71.
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
Fitzpatrick JM, Bellmunt J, Dreicer R, Fleshner NE, Logothetis CJ, Moul JW, Tombal B, Zlotta A
Maximizing outcomes in genitourinary cancers across the treatment continuum. BJU Int. 2011 Apr; 107 Suppl 2:1-12.
Maximizing outcomes in genitourinary cancers across the treatment continuum.
Gore ME, Bellmunt J, Eisen T, Escudier B, Mickisch G, Patard J, Porta C, Ravaud A, Schmidinger M, Schöffski P, Sternberg CN, Szczylik C, De Nigris E, Wheeler C, Kirpekar S
European journal of cancer (Oxford, England : 1990)
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology. Eur J Cancer. 2012 May; 48(7):1038-47.
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology.
Felip E, Rovirosa MA, Salud A, Capdevila F, Bellmunt J, Giralt J
Orbital metastases from transitional-cell cancer of the urinary bladder. Urol Int. 1991; 46(1):82-4.
Orbital metastases from transitional-cell cancer of the urinary bladder.
Intermittent chemotherapy in metastatic androgen-independent prostate cancer. BJU Int. 2007 Sep; 100(3):490-2.
Intermittent chemotherapy in metastatic androgen-independent prostate cancer.
Carles J, Esteban E, Climent M, Font A, Gonzalez-Larriba JL, Berrocal A, Garcia-Ribas I, Marfa X, Fabregat X, Albanell J, Bellmunt J
Annals of oncology : official journal of the European Society for Medical Oncology
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol. 2007 Aug; 18(8):1359-62.
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
Bellmunt J, Flodgren P, Roigas J, Oudard S
Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. BJU Int. 2009 Jul; 104(1):10-8.
Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.
Negrier S, Jäger E, Porta C, McDermott D, Moore M, Bellmunt J, Anderson S, Cihon F, Lewis J, Escudier B, Bukowski R
Medical oncology (Northwood, London, England)
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol. 2010 Sep; 27(3):899-906.
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
Bellmunt J, Trigo JM, Calvo E, Carles J, Pérez-Gracia JL, Rubió J, Virizuela JA, López R, Lázaro M, Albanell J
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol. 2010 Apr; 11(4):350-7.
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Bellmunt J, Allende E, Navarro M, Morales S, Sans M, Jolis L, Garcia AA, Rubio D
Epithelioid hemangioendothelioma of the liver with myocardial metastases. Jpn J Clin Oncol. 1989 Jun; 19(2):153-8.
Epithelioid hemangioendothelioma of the liver with myocardial metastases.
Klaassen Z, Kamat AM, Kassouf W, Gontero P, Villavicencio H, Bellmunt J, van Rhijn BWG, Hartmann A, Catto JWF, Kulkarni GS
Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. Eur Urol. 2018 11; 74(5):597-608.
Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.
Rodriguez-Vida A, Perez-Gracia JL, Bellmunt J
Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes. Clin Cancer Res. 2018 12 15; 24(24):6115-6124.
Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes.
Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J, Yu EY, Niegisch G, Vaishampayan UN, Theodore C, Berthold DR, Srinivas S, Sridhar SS, Plimack ER, Rosenberg JE, Powles T, Galsky MD, Necchi A
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. J Urol. 2018 12; 200(6):1207-1214.
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G
Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012 Feb; 23(2):406-10.
Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.
Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol. 2011 Jun 10; 29(17):2432-8.
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.
Statins and the effect of BCG on bladder cancer. N Engl J Med. 2007 Mar 22; 356(12):1276; author reply 1276-7.
Statins and the effect of BCG on bladder cancer.
Felip E, Bellmunt J, Salud A, Capdevila F
[Symptomatic hypomagnesemia in a patient treated with cisplatin]. Med Clin (Barc). 1990 Jun 30; 95(5):196-7.
[Symptomatic hypomagnesemia in a patient treated with cisplatin].
Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR, Winquist E, Raghavan D, Marreaud S, Collette S, Sylvester R, de Wit R
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012 Apr 01; 30(10):1107-13.
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
Sonpavde G, Bellmunt J, Schutz F, Choueiri TK
The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep. 2012 Aug; 14(4):295-306.
The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients.
Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4. Biomedicines. 2018 Aug 02; 6(3).
Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4.
de Gracia J, Bravo C, Miravitlles M, Tallada N, Orriols R, Bellmunt J, Vendrell M, Morell F
The American review of respiratory disease
Diagnostic value of bronchoalveolar lavage in peripheral lung cancer. Am Rev Respir Dis. 1993 Mar; 147(3):649-52.
Diagnostic value of bronchoalveolar lavage in peripheral lung cancer.
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, Weinstein JN, Kwiatkowski DJ, Lerner SP
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2018 08 09; 174(4):1033.
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.
Navarro M, Almirante B, Bellmunt J, Jolis L
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
Fatal septic thrombophlebitis due to Salmonella enteritidis. Eur J Clin Microbiol Infect Dis. 1989 Jan; 8(1):82-3.
Fatal septic thrombophlebitis due to Salmonella enteritidis.
Gild P, Wankowicz SA, Sood A, von Landenberg N, Friedlander DF, Alanee S, Chun FKH, Fisch M, Menon M, Trinh QD, Bellmunt J, Abdollah F
Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis. Urol Oncol. 2018 10; 36(10):469.e1-469.e11.
Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis.
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev. 2010 Aug; 36(5):416-24.
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.
Bellmunt J, Maroto-Rey P, Trigo JM, Carles J, Guillem V, López-Martín JA, Antón-Torres A, Urruticoechea L
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. Clin Transl Oncol. 2010 Jul; 12(7):503-8.
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
Calvo E, Maroto P, del Muro XG, Climent MA, González-Larriba JL, Esteban E, López R, Paz-Ares L, Bellmunt J, Castellano D
Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. Cancer Metastasis Rev. 2010 Aug; 29 Suppl 1:1-10.
Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma.
Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.
The Cancer Genome Atlas Project in Bladder Cancer. Cancer Treat Res. 2018; 175:259-271.
The Cancer Genome Atlas Project in Bladder Cancer.
Rovirosa A, Bellmunt J, López A, Fernández M, Guerra M, Montagut J
[The incidence of second neoplasms in advanced laryngeal cancer. Impact on survival]. Med Clin (Barc). 1994 Feb 05; 102(4):121-4.
[The incidence of second neoplasms in advanced laryngeal cancer. Impact on survival].
What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat Rev. 2013 Jun; 39(4):366-74.
What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
Prostate cancer. Multidisciplinary approach: a key to success. Crit Rev Oncol Hematol. 2008 Oct; 68 Suppl 1:S32-6.
Prostate cancer. Multidisciplinary approach: a key to success.
Prats J, Bellmunt J, Calvo MA, Sarrias F, Toran N
Orbital metastasis, by transitional cell carcinoma of the bladder. Int Urol Nephrol. 1989; 21(4):389-92.
Orbital metastasis, by transitional cell carcinoma of the bladder.
Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011 Apr; 78(1):24-32.
Experience with sorafenib and adverse event management.
Bellmunt J, Lalani AA, Jacobus S, Wankowicz SA, Polacek L, Takeda DY, Harshman LC, Wagle N, Moreno I, Lundgren K, Bossé D, Van Allen EM, Choueiri TK, Rosenberg JE
Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Br J Cancer. 2018 09; 119(6):707-712.
Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.
Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA
Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011 Feb 20; 29(6):632-8.
Congestive heart failure risk in patients with breast cancer treated with bevacizumab.
Sonpavde G, Attard G, Bellmunt J, Mason MD, Malavaud B, Tombal B, Sternberg CN
The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol. 2011 Aug; 60(2):270-8.
The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, González del Alba A, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Rodríguez-Antona C
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011 11; 12(12):1143-50.
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Gómez-Martín C, Salazar R, Montagut C, Gil-Martín M, Núñez JA, Puig M, Lin X, Khosravan R, Tursi JM, Lechuga MJ, Bellmunt J
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Invest New Drugs. 2013 Apr; 31(2):390-8.
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.
Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients. Eur Urol. 2013 Feb; 63(2):198-200.
Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients.
Necchi A, Pond GR, Moschini M, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Vaishampayan U, Theodore C, Sridhar SS, Rosenberg JE, Bellmunt J, Gallina A, Colombo R, Montorsi F, Briganti A, Galsky MD
Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer. 2019 Feb; 17(1):7-14.e3.
Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
Carles J, Gallardo E, Doménech M, Font A, Bellmunt J, Figols M, Mellado B, Sáez MI, Suárez C, Méndez MJ, Maroto P, Luque R, de Portugal T, Aldabo R, Bonfill T, Morales-Barrera R, García J, Maciá S, Maldonado X, Foro P
International journal of radiation oncology, biology, physics
Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. Int J Radiat Oncol Biol Phys. 2019 02 01; 103(2):344-352.
Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.
Ribas A, Albanell J, Solé-Calvo LA, Gallardo E, Bellmunt J, Vera R, Vidal R, Carulla J, Baselga J
Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma. Cancer. 1998 Mar 01; 82(5):878-85.
Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
Open to debate. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival. Eur Urol. 2008 Nov; 54(5):1192-7.
Open to debate. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival.
Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg OW, Herr H, Lechevallier E, Ribal MJ
Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol. 2012 Aug; 62(2):290-302.
Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature.
Ribas A, Albanell J, Bellmunt J, Solé-Calvo LA, Bermejo B, Gallardo E, Vidal R, Vera R, Eres N, Carulla J, Baselga J
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. J Clin Oncol. 1996 May; 14(5):1573-80.
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
Salud A, Porcel JM, Rovirosa A, Bellmunt J
Endobronchial metastatic disease: analysis of 32 cases. J Surg Oncol. 1996 Aug; 62(4):249-52.
Endobronchial metastatic disease: analysis of 32 cases.
Montalbán J, Molins A, Fernández JL, Romero F, Bellmunt J, Alvarez J, Codina Puiggrós A
[Solitary cerebellar metastases: a clinical neuro-radiological study]. Neurologia. 1988 Jan-Feb; 3(1):3-8.
[Solitary cerebellar metastases: a clinical neuro-radiological study].
[Gene therapy: new prospects in the treatment of cancer]. Med Clin (Barc). 1994 Dec 10; 103(20):776-9.
[Gene therapy: new prospects in the treatment of cancer].
Bellmunt J, Ribas A, Albanell J, Bermejo B, Vera R, De Torres JA, Morote J, Lopez-Pacios MA, Banus JM, Rovirosa A, Carulla J, Sole LA
M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder. Am J Clin Oncol. 1996 Aug; 19(4):344-8.
M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder.
[Bilateral choroidal metastasis as a form of presentation of pulmonary carcinoma]. Med Clin (Barc). 1994 Feb 12; 102(5):196-7.
[Bilateral choroidal metastasis as a form of presentation of pulmonary carcinoma].
Gallego-Melcón S, Sánchez de Toledo J, Doste D, López D, Moraga F, Rodríguez C, Vidal T, Bellmunt J
Late recurrent metastasis in Wilms' tumour. Med Pediatr Oncol. 1994; 23(2):158-61.
Late recurrent metastasis in Wilms' tumour.
Del Bene G, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Niegisch G, Bellmunt J, Baniel J, Galsky MD, Sternberg CN
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. Front Oncol. 2018; 8:463.
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database.
Bellmunt J, Calvo E, Castellano D, Climent MA, Esteban E, García del Muro X, González-Larriba JL, Maroto P, Trigo JM
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemother Pharmacol. 2009 Mar; 63 Suppl 1:S1-13.
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.
New agents for bladder cancer. Ann Oncol. 2010 Oct; 21 Suppl 7:vii56-8.
Mickisch GH, Schwander B, Escudier B, Bellmunt J, Maroto JP, Porta C, Walzer S, Siebert U
ClinicoEconomics and outcomes research : CEOR
Indirect treatment comparison of bevacizumab + interferon-a-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. Clinicoecon Outcomes Res. 2011; 3:19-27.
Indirect treatment comparison of bevacizumab + interferon-a-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.
González Larriba JL, Espinosa E, García Carbonero I, García-Donas J, López M, Meana A, Puente J, Bellmunt J
Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. Cancer Metastasis Rev. 2012 Sep; 31 Suppl 1:S11-7.
Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.
Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer. 2019 02 15; 125(4):533-540.
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Nassar AH, Umeton R, Kim J, Lundgren K, Harshman L, Van Allen EM, Preston M, Dong F, Bellmunt J, Mouw KW, Choueiri TK, Sonpavde G, Kwiatkowski DJ
Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clin Cancer Res. 2019 04 15; 25(8):2458-2470.
Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
Ribas A, Bellmunt J, Albanell J, Capdevila JA, Ocaña I, Gallego OS, Maldonado J, Giralt J, Solé LA
Malignant lymphoproliferative diseases in HIV-seropositive patients. A study of 40 cases at a single institution in Spain. Acta Oncol. 1995; 34(1):75-82.
Malignant lymphoproliferative diseases in HIV-seropositive patients. A study of 40 cases at a single institution in Spain.
Ribas A, Gallardo E, Vera R, Casado S, Vidal R, Bellmunt J
Clinical oncology (Royal College of Radiologists (Great Britain))
Life-threatening toxicity of oral tegafur-uracil (UFT) plus leucovorin. Clin Oncol (R Coll Radiol). 1997; 9(4):269-70.
Life-threatening toxicity of oral tegafur-uracil (UFT) plus leucovorin.
Molina R, Segui MA, Climent MA, Bellmunt J, Albanelll J, Fernandez M, Filella X, Jo J, Gimenez N, Iglesias E, Miralles M, Alonso C, Peiro G, Perez-Picañol E, Ballesta AM
p53 oncoprotein as a prognostic indicator in patients with breast cancer. Anticancer Res. 1998 Jan-Feb; 18(1B):507-11.
p53 oncoprotein as a prognostic indicator in patients with breast cancer.
Buesa JM, López-Pousa A, Martín J, Antón A, García del Muro J, Bellmunt J, Arranz F, Valentí V, Escudero P, Menéndez D, Casado A, Poveda A
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) Ann Oncol. 1998 Aug; 9(8):871-6.
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)
New chemotherapy combinations for advanced bladder cancer. Curr Opin Urol. 2001 Sep; 11(5):517-22.
New chemotherapy combinations for advanced bladder cancer.
Rovirosa A, Salud A, Felip E, Capdevila F, Giralt J, Bellmunt J
Cavitary pulmonary metastases in transitional cell carcinoma of the urinary bladder. Urol Int. 1992; 48(1):102-4.
Cavitary pulmonary metastases in transitional cell carcinoma of the urinary bladder.
Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A
Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int. 2007 Feb; 99(2):274-80.
Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009 May; 20 Suppl 4:79-80.
Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, Choueiri T, Bukowski R, Motzer R, Kirkali Z, Mulders P, Bellmunt J
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol. 2011 Oct; 60(4):684-90.
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ, Sankin AI, Schoenberg MP, Shipley WU, Villers A, Efstathiou JA, Bellmunt J, Stenzl A
SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World J Urol. 2019 Jan; 37(1):61-83.
SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.
Procopio G, Bellmunt J, Dutcher J, Bracarda S, Knox J, Brueckner A, Molnar I, Escudier B, Hutson TE
Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer. 2013 Feb 05; 108(2):311-8.
Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis.
Kim J, Kwiatkowski D, McConkey DJ, Meeks JJ, Freeman SS, Bellmunt J, Getz G, Lerner SP
The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. Eur Urol. 2019 06; 75(6):961-964.
The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.
Antineoplastic Combined Chemotherapy Protocols
Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U, Ladoire S, Theodore C, Agarwal N, Yu EY, Niegisch G, Sternberg CN, Srinivas S, Vaishampayan U, Necchi A, Liontos M, Rosenberg JE, Powles T, Bellmunt J, Galsky MD
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. Oncologist. 2019 10; 24(10):1348-1355.
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer.
Treatment of Metastatic Urothelial Cancer in 2018. JAMA Oncol. 2019 Jun 01; 5(6):904-905.
Treatment of Metastatic Urothelial Cancer in 2018.
Martínez-Bosch N, Rodriguez-Vida A, Juanpere N, Lloreta J, Rovira A, Albanell J, Bellmunt J, Navarro P
Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities. Nat Rev Urol. 2019 07; 16(7):433-445.
Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities.
Segalés L, Juanpere N, Lorenzo M, Albero-González R, Fumadó L, Cecchini L, Bellmunt J, Lloreta-Trull J, Hernández-Llodrà S
Virchows Archiv : an international journal of pathology
Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome. Virchows Arch. 2019 Oct; 475(4):457-466.
Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome.
Immunotherapy in non-metastatic urothelial cancer: back to the 'future'. Expert Opin Biol Ther. 2019 07; 19(7):685-695.
Immunotherapy in non-metastatic urothelial cancer: back to the 'future'.
Management of metastatic bladder cancer. Cancer Treat Rev. 2019 Jun; 76:10-21.
Management of metastatic bladder cancer.
Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019 06 01; 30(6):970-976.
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
Hanna N, Trinh QD, Seisen T, Vetterlein MW, Sammon J, Preston MA, Lipsitz SR, Bellmunt J, Menon M, Choueiri TK, Abdollah F
Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. Eur Urol Oncol. 2018 05; 1(1):83-90.
Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.
Hernández-Llodrà S, Segalés L, Safont A, Juanpere N, Lorenzo M, Fumadó L, Rodríguez-Vida A, Cecchini L, Bellmunt J, Lloreta-Trull J
SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer. Prostate. 2019 07; 79(10):1156-1165.
SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Jerome and Nancy Kohlberg Professor of Medicine
Hernández-Prat A, Rodriguez-Vida A, Juanpere-Rodero N, Arpi O, Menéndez S, Soria-Jiménez L, Martínez A, Iarchouk N, Rojo F, Albanell J, Brake R, Rovira A, Bellmunt J
Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Ka Inhibitor TAK-117 in Preclinical Bladder Cancer Models. Mol Cancer Res. 2019 09; 17(9):1931-1944.
Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Ka Inhibitor TAK-117 in Preclinical Bladder Cancer Models.
Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan U, Théodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. Eur Urol Oncol. 2019 05; 2(3):248-256.
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
Grimm MO, Bex A, De Santis M, Ljungberg B, Catto JWF, Rouprêt M, Hussain SA, Bellmunt J, Powles T, Wirth M, Van Poppel H
Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. Eur Urol. 2019 Sep; 76(3):368-380.
Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019.
Bellmunt J, Kim J, Reardon B, Perera-Bel J, Orsola A, Rodriguez-Vida A, Wankowicz SA, Bowden M, Barletta JA, Morote J, de Torres I, Juanpere N, Lloreta-Trull J, Hernandez S, Mouw KW, Taplin ME, Cejas P, Long HW, Van Allen EM, Getz G, Kwiatkowski DJ
Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Cancer Res. 2020 10 15; 80(20):4476-4486.
Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 04; 22(4):525-537.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma - Author's reply. Lancet Oncol. 2021 06; 22(6):e238.
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma - Author's reply.
Labaki C, Saad E, Choueiri TK, Bellmunt J
Oligometastatic Bladder Cancer: Defining a Novel Entity. Eur Urol. 2023 10; 84(4):390-392.
Oligometastatic Bladder Cancer: Defining a Novel Entity.
McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, Mantia CM, Wei XX, Berchuck JE, Berg SA, Ravi PK, Michaelson MD, Choueiri TK, Bellmunt J
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Ann Oncol. 2024 Jan; 35(1):91-97.
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind? Med. 2024 Jun 14; 5(6):490-492.
Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
Bellmunt J, Maroto P, Bonfill T, Vazquez F, Perez-Gracia JL, Juanpere N, Hernandez-Prat A, Hernandez-Llodra S, Rovira A, Juan O, Rodriguez-Vida A
Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study. Clin Genitourin Cancer. 2024 Oct; 22(5):102123.
Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.
Cebrian V, Alvarez M, Aleman A, Palou J, Bellmunt J, Gonzalez-Peramato P, Cordón-Cardo C, García J, Piulats JM, Sánchez-Carbayo M
Discovery of myopodin methylation in bladder cancer. J Pathol. 2008 Sep; 216(1):111-9.
Discovery of myopodin methylation in bladder cancer.
Bracarda S, Montironi R, Porta C, Szczylic C, Bearz A, Cartenì G, Bellmunt J
The treating scenario in genitourinary oncology: what is new? Part 1. Future Oncol. 2013 Jun; 9(6):797-801.
The treating scenario in genitourinary oncology: what is new? Part 1.
Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist. 2013; 18(5):558-67.
Perspectives on treatment of metastatic castration-resistant prostate cancer.
The treating scenario in genitourinary oncology: what is new? Part 2. Future Oncol. 2013 Jun; 9(6):803-6.
The treating scenario in genitourinary oncology: what is new? Part 2.
Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. Br J Cancer. 2013 Jul 09; 109(1):121-30.
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
Stage II disease, elderly patients, secondary neoplasms, and the MOSAIC trial. J Clin Oncol. 2013 Apr 20; 31(12):1609.
Stage II disease, elderly patients, secondary neoplasms, and the MOSAIC trial.
de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. Br J Cancer. 2013 Jun 25; 108(12):2565-72.
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.
Bellmunt J, Fougeray R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y, Culine S, Choueiri TK
Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013 Jun; 24(6):1466-72.
Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
Targeted therapies and the treatment of non-clear cell renal cell carcinoma. Ann Oncol. 2013 Jul; 24(7):1730-1740.
Targeted therapies and the treatment of non-clear cell renal cell carcinoma.
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist. 2013; 18(6):775.
Majumdar S, Gong EM, Di Vizio D, Dreyfuss J, Degraff DJ, Hager MH, Park PJ, Bellmunt J, Matusik RJ, Rosenberg JE, Adam RM
Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior. Neoplasia. 2013 Jul; 15(7):749-60.
Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.
Zhang TY, Agarwal N, Sonpavde G, DiLorenzo G, Bellmunt J, Vogelzang NJ
Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. Curr Urol Rep. 2013 Jun; 14(3):174-83.
Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments.
A new approach to second-line therapy for urothelial cancer? Lancet Oncol. 2013 Jul; 14(8):682-4.
A new approach to second-line therapy for urothelial cancer?
Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy. Curr Opin Urol. 2013 Sep; 23(5):466-71.
Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy.
López V, González-Peramato P, Suela J, Serrano A, Algaba F, Cigudosa JC, Vidal A, Bellmunt J, Heredero O, Sánchez-Carbayo M
Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA. J Transl Med. 2013 Aug 01; 11:182.
Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA.
Castellano D, Duh MS, Korves C, Suthoff ED, Neary M, Hernández Pastor LJ, Bellmunt J
Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain. Expert Opin Drug Saf. 2013 Jul; 12(4):455-63.
Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain.
Sonpavde G, Je Y, Schutz F, Galsky MD, Paluri R, Rosenberg JE, Bellmunt J, Choueiri TK
Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2013 Jul; 87(1):80-9.
Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.
Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, Bellmunt J
Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014 Jul; 66(1):42-54.
Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials.
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist. 2013; 18(8):971.
Combination therapy in metastatic renal cell cancer. Semin Oncol. 2013 Aug; 40(4):472-81.
Combination therapy in metastatic renal cell cancer.
Garcia-Donas J, Leandro-García LJ, González Del Alba A, Morente M, Alemany I, Esteban E, Arranz JA, Climent MA, Gallardo E, Castellano DE, Bellmunt J, Mellado B, Puente J, Moreno F, Font A, Hernando S, Robledo M, Rodríguez-Antona C
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol. 2013 Sep; 24(9):2409-14.
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
Bellmunt J, Teh BT, Tortora G, Rosenberg JE
Molecular targets on the horizon for kidney and urothelial cancer. Nat Rev Clin Oncol. 2013 Oct; 10(10):557-70.
Molecular targets on the horizon for kidney and urothelial cancer.
Melichar B, Bracarda S, Matveev V, Alekseev B, Ivanov S, Zyryanov A, Janciauskiene R, Fernebro E, Mulders P, Osborne S, Jethwa S, Mickisch G, Gore M, van Moorselaar RJ, Staehler M, Magne N, Bellmunt J
A multinational phase II trial of bevacizumab with low-dose interferon-a2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann Oncol. 2013 Sep; 24(9):2396-402.
A multinational phase II trial of bevacizumab with low-dose interferon-a2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.
Gallardo E, Arranz JÁ, Maroto JP, León LÁ, Bellmunt J
Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel. Crit Rev Oncol Hematol. 2013 Nov; 88(2):357-67.
Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. Eur Urol. 2013 Dec; 64(6):994-1002.
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.
Paglino C, Procopio G, Sabbatini R, Bellmunt J, Schmidinger M, Bearz A, Bamias A, Melichar B, Imarisio I, Tinelli C, Porta C
A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. Anticancer Res. 2013 Nov; 33(11):4999-5004.
A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.
Harshman LC, Fougeray R, Choueiri TK, Schutz FA, Salhi Y, Rosenberg JE, Bellmunt J
The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine. Br J Cancer. 2013 Nov 12; 109(10):2548-53.
The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine.
Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, Bellmunt J, Rha SY, Sun JM, Nathan P, Feinberg BA, Scott J, McDermott R, Ahn JH, Wagstaff J, Chang YH, Ou YC, Donnellan P, Huang CY, McCaffrey J, Chiang PH, Chuang CK, Korves C, Neary MP, Diaz JR, Mehmud F, Duh MS
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol. 2014 Jan; 44(1):5-16.
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
Sternberg CN, Skoneczna IA, Castellano D, Theodore C, Blais N, Voog E, Bellmunt J, Peters F, Le-Guennec S, Cerbone L, Risse ML, Machiels JP
Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB). Oncology. 2013; 85(4):208-15.
Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB).
Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer. 2013 Dec; 11(4):495-500.
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013 Dec; 14(13):1307-16.
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
Sunitinib malate in the treatment of urothelial cancer. Expert Opin Investig Drugs. 2014 Jan; 23(1):115-24.
Sunitinib malate in the treatment of urothelial cancer.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014 Jan; 65(1):124-37.
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
Guancial EA, Bellmunt J, Yeh S, Rosenberg JE, Berman DM
The evolving understanding of microRNA in bladder cancer. Urol Oncol. 2014 Jan; 32(1):41.e31-40.
The evolving understanding of microRNA in bladder cancer.
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014 Feb; 65(2):467-79.
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Hyponatremia associated with worse outcomes in metastatic renal cell cancer: a potential target for intervention? Eur Urol. 2014 Apr; 65(4):731-2.
Hyponatremia associated with worse outcomes in metastatic renal cell cancer: a potential target for intervention?
Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, Choueiri TK, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia DI, Chekaluk Y, Kwiatkowski DJ, Bochner BH, Hahn WC, Ligon AH, Barletta JA, Loda M, Berman DM, Kantoff PW, Michor F, Rosenberg JE
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1873-83.
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.
Reply from authors re: Cora N. Sternberg, Richard Sylvester. Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2014;66:55-6. Eur Urol. 2014 Jul; 66(1):57-8.
Reply from authors re: Cora N. Sternberg, Richard Sylvester. Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2014;66:55-6.
Leow JJ, Reese S, Trinh QD, Bellmunt J, Chung BI, Kibel AS, Chang SL
Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis. BJU Int. 2015 May; 115(5):713-21.
Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis.
Leow JJ, Reese SW, Jiang W, Lipsitz SR, Bellmunt J, Trinh QD, Chung BI, Kibel AS, Chang SL
Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur Urol. 2014 Sep; 66(3):569-76.
Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States.
Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J
A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol. 2014 Sep; 66(3):529-41.
A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.
Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):130-7.
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.
Prior C, Perez-Gracia JL, Garcia-Donas J, Rodriguez-Antona C, Guruceaga E, Esteban E, Suarez C, Castellano D, del Alba AG, Lozano MD, Carles J, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Gurpide A, Lopez-Picazo JM, Hernandez AG, Mellado B, Martínez E, Moreno F, Font A, Calvo A
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One. 2014; 9(1):e86263.
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, Escudier B
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol. 2014 Mar 10; 32(8):752-9.
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
In reply. Oncologist. 2014 Mar; 19(3):305-6.
New treatments for bladder cancer: when will we make progress? Curr Treat Options Oncol. 2014 Mar; 15(1):99-114.
New treatments for bladder cancer: when will we make progress?
Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. Future Oncol. 2014 Feb; 10(3):351-62.
Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial.
Castellano DE, Bellmunt J, Maroto JP, Font-Pous A, Morales-Barrera R, Ghanem I, Suarez C, Martín Lorente C, Etxaniz O, Capdevila L, Coronado C, Alfaro V, Siguero M, Fernández-Teruel C, Carles J
Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen. Cancer Chemother Pharmacol. 2014 Apr; 73(4):857-67.
Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.
Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014 May; 113(5b):E137-43.
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy. Eur J Cancer. 2014 May; 50(7):1321-9.
Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy.
Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
Fay AP, Elfiky A, Teló GH, McKay RR, Kaymakcalan M, Nguyen PL, Vaidya A, Ruan DT, Bellmunt J, Choueiri TK
Adrenocortical carcinoma: the management of metastatic disease. Crit Rev Oncol Hematol. 2014 Nov; 92(2):123-32.
Adrenocortical carcinoma: the management of metastatic disease.
Boll LM, Vázquez Montes de Oca S, Camarena ME, Castelo R, Bellmunt J, Perera-Bel J, Albà MM
Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts. Nat Commun. 2025 Feb 20; 16(1):1213.
Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts.
Bellmunt J, Powles T, Park SH, Voog E, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Sternberg CN, Aragon-Ching JB, Petrylak DP, Climent Duran MA, Tyroller K, Hoffman J, Jacob N, Grivas P, Gupta S
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease. Eur Urol. 2025 Oct; 88(4):331-338.
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease.
Progress in systemic therapy for advanced-stage urothelial carcinoma. Nat Rev Clin Oncol. 2024 Jan; 21(1):8-27.
Progress in systemic therapy for advanced-stage urothelial carcinoma.
Rodriguez-Vida A, Valderrama BP, Castellano D, Pinto A, Mellado B, Puente J, Climent MA, Domenech M, Vazquez F, Perez-Gracia JL, Bonfill T, Morales-Barrera R, Gonzalez-Billalabeitia E, Garcia-Del-Muro X, Maroto P, Navarro-Gorro N, Juanpere N, Juan O, Bellmunt J
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study. ESMO Open. 2024 Sep; 9(9):103690.
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study.
Rodriguez-Vida A, Maroto P, Font A, Martin C, Mellado B, Corbera A, Orrillo M, Reig O, Querol R, Rios-Hoyo A, Cano L, Alonso J, Martinez G, Galtes S, Taus A, Martinez-Garcia M, Juanpere N, Juan O, Bellmunt J
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. Br J Cancer. 2023 01; 128(1):21-29.
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer. 2014 Jun; 50(9):1617-27.
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Unveiling the surgical risk associated with neoadjuvant chemotherapy in bladder cancer. BJU Int. 2014 Aug; 114(2):163-4.
Unveiling the surgical risk associated with neoadjuvant chemotherapy in bladder cancer.
Bellmunt J, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, Bellosillo B, Werner L, Mullane S, Fay AP, O'Brien R, Barretina J, Minoche AE, Signoretti S, Montagut C, Himmelbauer H, Berman DM, Kantoff P, Choueiri TK, Rosenberg JE
Identification of ALK gene alterations in urothelial carcinoma. PLoS One. 2014; 9(8):e103325.
Identification of ALK gene alterations in urothelial carcinoma.
Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, Garraway LA, Riester M, Michor F, Kantoff PW, Rosenberg JE
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014 Aug; 3(4):835-44.
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.
Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, Choueiri TK
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. Clin Genitourin Cancer. 2014 Aug; 12(4):262-9.
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J, Suarez C, Gallardo E, Rodon J, Pons F, Bonfill T, Beltran M, Moya I, Galtes S, Albanell J, Carles J
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma. Oncologist. 2014 Sep; 19(9):917-8.
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep; 25 Suppl 3:iii40-8.
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up.
Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J
New agents for prostate cancer. Ann Oncol. 2014 Sep; 25(9):1700-1709.
Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, Bellmunt J, Song J, Carvo I, Lampron M, Stanton ML, Hodi FS, McDermott DF, Atkins MB, Freeman GJ, Hirsch MS, Signoretti S
PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014 Nov; 25(11):2178-2184.
PD-L1 expression in nonclear-cell renal cell carcinoma.
Bellmunt J, Puente J, Garcia de Muro J, Lainez N, Rodríguez C, Duran I
SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol. 2014 Dec; 16(12):1043-50.
SEOM clinical guidelines for the treatment of renal cell carcinoma.
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014 Nov 27; 515(7528):558-62.
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Sonpavde G, Bellmunt J, Rosenberg JE, Regazzi AM, Bajorin DF, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Dec; 12(6):395-8.
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.
The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67(1):30-32.
The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer.
Plimack ER, Hoffman-Censits J, Rosenberg JE, Wong YN, Bellmunt J, Choueiri TK
Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. J Clin Oncol. 2014 Dec 20; 32(36):4171-2.
Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye.
Merseburger AS, Scher HI, Bellmunt J, Miller K, Mulders PF, Stenzl A, Sternberg CN, Fizazi K, Hirmand M, Franks B, Haas GP, de Bono J, de Wit R
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int. 2015 Jan; 115(1):41-9.
Enzalutamide in European and North American men participating in the AFFIRM trial.
Pond GR, Bellmunt J, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Sonpavde G
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. Clin Genitourin Cancer. 2015 Feb; 13(1):71-9.
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.
Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, McDermott R, Wagstaff J, Donnellan P, McCaffrey J, Vekeman F, Neary MP, Diaz J, Mehmud F, Duh MS
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med. 2014 Dec; 3(6):1517-26.
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.
Orsola A, Werner L, de Torres I, Martin-Doyle W, Raventos CX, Lozano F, Mullane SA, Leow JJ, Barletta JA, Bellmunt J, Morote J
Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients. Br J Cancer. 2015 Feb 03; 112(3):468-74.
Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients.
Martin-Doyle W, Leow JJ, Orsola A, Chang SL, Bellmunt J
Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol. 2015 Feb 20; 33(6):643-50.
Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients.
A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treat Rev. 2015 Apr; 41(4):310-9.
A contemporary review of management and prognostic factors of upper tract urothelial carcinoma.
Montgomery B, Kheoh T, Molina A, Li J, Bellmunt J, Tran N, Loriot Y, Efstathiou E, Ryan CJ, Scher HI, de Bono JS
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Eur Urol. 2015 May; 67(5):866-73.
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Dreicer R, Chen YH, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Bellmunt J
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clin Genitourin Cancer. 2015 Apr; 13(2):185-92.
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.
Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S, González I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sánchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A, Montagut C
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clin Cancer Res. 2015 May 01; 21(9):2157-66.
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.
Hematology/oncology clinics of North America
Bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):xiii-xiv.
Bellmunt J, Werner L, Leow JJ, Mullane SA, Fay AP, Riester M, Van Hummelen P, Taplin ME, Choueiri TK, Van Allen E, Rosenberg J
Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. PLoS One. 2015; 10(6):e0124711.
Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.
Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change? Oncologist. 2015 May; 20(5):461-3.
Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?
Necchi A, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, Bellmunt J, Sonpavde G
Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. Clin Genitourin Cancer. 2015 Apr; 13(2):178-84.
Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy.
Bellmunt J, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, Taplin ME, Choueiri TK, Hodi FS, Freeman GJ, Signoretti S
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015 Apr; 26(4):812-817.
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.
Current role of cabozantinib in metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2015 Feb; 15(2):151-6.
Current role of cabozantinib in metastatic castration-resistant prostate cancer.
Bambury RM, Bhatt AS, Riester M, Pedamallu CS, Duke F, Bellmunt J, Stack EC, Werner L, Park R, Iyer G, Loda M, Kantoff PW, Michor F, Meyerson M, Rosenberg JE
DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC Cancer. 2015 Apr 09; 15:242.
DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors.
Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015 Apr; 16(4):417-25.
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Fay AP, Signoretti S, Callea M, Tel? GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, Bellmunt J, Hodi FS, Freeman GJ, Elfiky A, Choueiri TK
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015; 3:3.
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.
Sonpavde G, Jones BS, Bellmunt J, Choueiri TK, Sternberg CN
Future directions and targeted therapies in bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):361-76, x.
Future directions and targeted therapies in bladder cancer.
Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015 Mar 01; 33(7):723-31.
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.
Perioperative therapy for muscle invasive bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):301-18, ix.
Perioperative therapy for muscle invasive bladder cancer.
Fuertes J, Montagut C, Bullich S, Coma MI, Mestre-Fusco A, Suárez-Piñera M, Trampal C, Bellmunt J
Revista espanola de medicina nuclear e imagen molecular
Incidental focal uptake in colorectal location on oncologic ¹8FDG PET and PET/CT studies: histopathological findings and clinical significances. Rev Esp Med Nucl Imagen Mol. 2015 Mar-Apr; 34(2):95-101.
Incidental focal uptake in colorectal location on oncologic ¹8FDG PET and PET/CT studies: histopathological findings and clinical significances.
Fizazi K, Abrahamsson PA, Ahlgren G, Bellmunt J, Castellano D, Culine S, de Wit R, Gillessen S, Gschwend JE, Hamdy F, James N, McDermott R, Miller K, Wiegel T, Wirth M, Tombal B
Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol. 2015 May; 67(5):904-12.
Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.
Sonpavde G, Pond GR, Mullane S, Qu AQ, Di Lorenzo G, Federico P, Necchi A, Rosenberg JE, Bellmunt J, Choueiri TK
Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. Clin Genitourin Cancer. 2015 Jun; 13(3):250-6.
Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design.
Gore ME, Bellmunt J, Eisen T, Escudier B, Mickisch G, Patard J, Porta C, Ravaud A, Schmidinger M, Schöffski P, Sternberg CN, Szczylik C, Lewis S, Kirpekar S
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT). Eur J Cancer. 2014 Dec; 50(18):3153-60.
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT).
Sonpavde G, Pond GR, Fougeray R, Bellmunt J
Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma. BJU Int. 2015 Jun; 115(6):854-5.
Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma.
Murta-Nascimento C, Romero AI, Sala M, Lorente JA, Bellmunt J, Rodero NJ, Lloreta J, Hospital À, Burón A, Castells X, Macià F
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona. Eur J Cancer Prev. 2015 Jul; 24(4):335-9.
The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona.
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug 01; 121(15):2586-93.
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Choueiri TK, Loda M, Stack E, Rosenberg J
HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015 Jun; 4(6):844-52.
HER2 as a target in invasive urothelial carcinoma.
Cole AP, Dalela D, Hanske J, Mullane SA, Choueiri TK, Meyer CP, Nguyen PL, Menon M, Kibel AS, Preston MA, Bellmunt J, Trinh QD
Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urol Oncol. 2015 Dec; 33(12):504.e9-17.
Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010.
Precision and predictive medicine in urothelial cancer: are we making progress? Eur Urol. 2015 Oct; 68(4):547-9.
Precision and predictive medicine in urothelial cancer: are we making progress?
Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer? BJU Int. 2015 Oct; 116(4):500-1.
Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer?
Suárez C, Puente J, Gallardo E, Méndez-Vidal MJ, Climent MA, León L, Olmos D, García del Muro X, González-Billalabeitia E, Grande E, Bellmunt J, Mellado B, Maroto P, González del Alba A
New advances in genitourinary cancer: evidence gathered in 2014. Cancer Metastasis Rev. 2015 Sep; 34(3):443-64.
New advances in genitourinary cancer: evidence gathered in 2014.
Harshman LC, Preston MA, Bellmunt J, Beard C
Diagnosis of Bladder Carcinoma: A Clinician's Perspective. Surg Pathol Clin. 2015 Dec; 8(4):677-85.
Diagnosis of Bladder Carcinoma: A Clinician's Perspective.
Raggi D, Miceli R, Sonpavde G, Giannatempo P, Mariani L, Galsky MD, Bellmunt J, Necchi A
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 2016 Jan; 27(1):49-61.
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
de Velasco G, Krajewski KM, Albiges L, Awad MM, Bellmunt J, Hodi FS, Choueiri TK
Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2016 Jan; 4(1):12-7.
Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.
Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, de Velasco G, Tyburczy ME, Hamieh L, Albiges L, Agarwal N, Ho TH, Song J, Pignon JC, Barrios PM, Michaelson MD, Van Allen E, Krajewski KM, Porta C, Pal S, Bellmunt J, McDermott DF, Heng DYC, Gray KP, Signoretti S
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 05 15; 22(10):2445-2452.
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
De Santis M, Wiechno PJ, Bellmunt J, Lucas C, Su WC, Albiges L, Lin CC, Senkus-Konefka E, Flechon A, Mourey L, Necchi A, Loidl WC, Retz MM, Vaissière N, Culine S
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Ann Oncol. 2016 Mar; 27(3):449-54.
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).
Chi KN, Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, Rathkopf DE, Fizazi K, Kantoff PW, Li J, Azad AA, Eigl BJ, Heng DY, Joshua AM, de Bono JS, Scher HI
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2016 Mar; 27(3):454-60.
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.
Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Choueiri TK, Necchi A, Di Lorenzo G, Bellmunt J
Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. J Urol. 2016 Feb; 195(2):277-82.
Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.
The evolving role of enzalutamide on the treatment of prostate cancer. Future Oncol. 2016 Mar; 12(5):607-16.
The evolving role of enzalutamide on the treatment of prostate cancer.
Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business? Eur Urol. 2016 Apr; 69(4):574-575.
Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business?
Sonpavde G, Pond GR, Choueiri TK, Mullane S, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Buonerba C, Rozzi A, Matsumoto K, Lee JL, Kitamura H, Kume H, Bellmunt J
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. Eur Urol. 2016 Apr; 69(4):634-641.
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer--At What Cost? Eur Urol 2016;69:642-44: Combination Chemotherapy as a Viable Salvage Therapy Strategy for Advanced Urothelial Carcinoma. Eur Urol. 2016 Apr; 69(4):644-645.
Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer--At What Cost? Eur Urol 2016;69:642-44: Combination Chemotherapy as a Viable Salvage Therapy Strategy for Advanced Urothelial Carcinoma.
Giannatempo P, Pond GR, Sonpavde G, Raggi D, Naik G, Galsky MD, Bellmunt J, Necchi A
The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Apr; 69(4):624-633.
The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 07; 387(10031):1909-20.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma. Nat Rev Urol. 2016 06; 13(6):306-7.
Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma.
Mullane SA, Werner L, Rosenberg J, Signoretti S, Callea M, Choueiri TK, Freeman GJ, Bellmunt J
Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Sci Rep. 2016 06 10; 6:27702.
Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma.
Cejas P, Li L, O'Neill NK, Duarte M, Rao P, Bowden M, Zhou CW, Mendiola M, Burgos E, Feliu J, Moreno-Rubio J, Guadalajara H, Moreno V, García-Olmo D, Bellmunt J, Mullane S, Hirsch M, Sweeney CJ, Richardson A, Liu XS, Brown M, Shivdasani RA, Long HW
Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nat Med. 2016 06; 22(6):685-91.
Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles.
van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, Matveev V, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N
Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. Eur Urol. 2016 05; 69(5):802-20.
Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.
Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Eur Urol. 2016 05; 69(5):924-32.
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Seisen T, Sun M, Leow JJ, Preston MA, Cole AP, Gelpi-Hammerschmidt F, Hanna N, Meyer CP, Kibel AS, Lipsitz SR, Nguyen PL, Bellmunt J, Choueiri TK, Trinh QD
Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 10 10; 34(29):3529-3536.
Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base.
Bellmunt J, Zhou CW, Mullane SA, Werner L, Taplin ME, Fay AP, Choueiri TK, Orsola A, Takeda DY, Hahn WC, Kim J, Sonpavde G, Bowden M
Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J Cancer. 2016 06 28; 115(1):12-9.
Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]
Urothelial carcinoma management in elderly or unfit patients. EJC Suppl. 2016 Mar; 14(1):1-20.
Urothelial carcinoma management in elderly or unfit patients.
Fay AP, de Velasco G, Ho TH, Van Allen EM, Murray B, Albiges L, Signoretti S, Hakimi AA, Stanton ML, Bellmunt J, McDermott DF, Atkins MB, Garraway LA, Kwiatkowski DJ, Choueiri TK
Journal of the National Comprehensive Cancer Network : JNCCN
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. J Natl Compr Canc Netw. 2016 07; 14(7):820-4.
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
McKay RR, De Velasco G, Werner L, Bellmunt J, Harshman L, Sweeney C, Rosenberg JE, Hirsch M, Signoretti S, Van Allen EM, Walsh M, Vaishampayan U, McDermott DF, Choueiri TK
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016 Aug 01; 122(15):2389-98.
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.
Mullane SA, Werner L, Guancial EA, Lis RT, Stack EC, Loda M, Kantoff PW, Choueiri TK, Rosenberg J, Bellmunt J
Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2016 08; 14(4):352-9.
Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.
Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, Bellmunt J, Choueiri TK, Elfiky AA, Harshman LC, McKay RR, Pomerantz MM, Sweeney CJ, Taplin ME, Kantoff PW, Nguyen PL
Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 08; 14(4):e299-305.
Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.
Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68:970-7. Eur Urol. 2016 09; 70(3):e71.
Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68:970-7.
Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, Rosenberg JE
Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016 Aug 01; 2(8):1094-6.
Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.
Cancer immunotherapy: new applications in urologic oncology. Curr Opin Urol. 2016 11; 26(6):556-63.
Cancer immunotherapy: new applications in urologic oncology.
Sonpavde G, Pond GR, Mullane S, Ramirez AA, Vogelzang NJ, Necchi A, Powles T, Bellmunt J
Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. BJU Int. 2017 04; 119(4):579-584.
Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol. 2017 02; 71(2):281-289.
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Sonpavde G, Pond GR, Di Lorenzo G, Buonerba C, Rozzi A, Lanzetta G, Necchi A, Giannatempo P, Raggi D, Matsumoto K, Choueiri TK, Mullane S, Niegisch G, Albers P, Lee JL, Kitamura H, Kume H, Bellmunt J
Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2016 12; 14(6):494-498.
Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.
Letter to the Editor, Re: van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, Fernández PL, Oosterwijk E, Schalken JA, Alcaraz A, Witjes JA. A five-gene expression signature to predict progression in T1G3 bladder cancer. Eur J Cancer. 2016; 64:127-136. Eur J Cancer. 2016 11; 68:196-197.
Letter to the Editor, Re: van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, Fernández PL, Oosterwijk E, Schalken JA, Alcaraz A, Witjes JA. A five-gene expression signature to predict progression in T1G3 bladder cancer. Eur J Cancer. 2016; 64:127-136.
Seisen T, Jindal T, Karabon P, Sood A, Bellmunt J, Rouprêt M, Leow JJ, Vetterlein MW, Sun M, Alanee S, Choueiri TK, Trinh QD, Menon M, Abdollah F
Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. Eur Urol. 2017 05; 71(5):714-718.
Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma.
Seisen T, Sun M, Lipsitz S, Abdollah F, Leow J, Menon M, Preston M, Harshman L, Kibel A, Nguyen P, Bellmunt J, Choueiri T, Trinh Q
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
Seisen T, Krasnow R, Rouprêt M, Lipsitz S, Leow J, Vetterlein M, Preston M, Kibel A, Choueiri T, Bellmunt J, Trinh Q, Chang S
Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer Med. 2017 01; 6(1):186-194.
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
Escudier BJ, Bellmunt J, Negrier S, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S
Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-a2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2009 May 20; 27(15_suppl):5020.
Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-a2a (IFN) in metastatic renal cell carcinoma (mRCC).
Hutson TE, Bellmunt J, Porta C, Staehler M, Szczylik C, Nadel A, Anderson S, Bukowski RM, Eisen T, Escudier B
Long-term safety of sorafenib (SOR) for the treatment (tx) of advanced clear-cell renal-cell carcinoma (RCC): Data analysis from patients (pts) treated for over 1 year in the phase III TARGET study. J Clin Oncol. 2009 May 20; 27(15_suppl):e16057.
Long-term safety of sorafenib (SOR) for the treatment (tx) of advanced clear-cell renal-cell carcinoma (RCC): Data analysis from patients (pts) treated for over 1 year in the phase III TARGET study.
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 01 07; 389(10064):67-76.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Guix M, Lema L, Lloreta J, Rojo F, Suárez C, Carles J, de la Cruz J, Sánchez-Carbayo M, Albanell J, Bellmunt J
Excision repair cross-complementing 1 (ERCC1) and survival in advanced bladder cancer: Confirmatory results using immunohistochemistry. J Clin Oncol. 2009 May 20; 27(15_suppl):5025.
Excision repair cross-complementing 1 (ERCC1) and survival in advanced bladder cancer: Confirmatory results using immunohistochemistry.
Paz-Ares LG, Solsona E, Esteban E, Saez A, Gonzalez-Larriba J, Anton A, Hevia M, de la Rosa F, Guillem V, Bellmunt J
Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol. 2010 Jun 20; 28(18_suppl):LBA4518.
Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study.
Sanchez-Carbayo M, Orenes E, Gil M, Piulats JM, Alvarez M, Bellmunt J, Palou J, Cordon-Cardo C, Ecke T, Lopez-Beltran A
Discovery of the methylation of the metastasis suppressor gene KiSS-1 in bladder cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):5023.
Discovery of the methylation of the metastasis suppressor gene KiSS-1 in bladder cancer.
Grau L, Ruppen I, Gil M, Piulats JM, Bellmunt J, Ashman K, Ecke T, Sanchez-Carbayo M
Differential protein expression profiling by iTRAQ-2DLC-MS/MS of human bladder cancer EJ138 cells transfected with the metastasis suppressor KiSS-1 gene. J Clin Oncol. 2009 May 20; 27(15_suppl):e16043.
Differential protein expression profiling by iTRAQ-2DLC-MS/MS of human bladder cancer EJ138 cells transfected with the metastasis suppressor KiSS-1 gene.
De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy MG, Daugaard G, Gil T, Maroto JP, Marreaud S, Sylvester R
Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986. J Clin Oncol. 2010 Jun 20; 28(18_suppl):LBA4519.
Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986.
Bellmunt J, Trigo J, Calvo E, Carles J, Perez-Gracia J, Rubió J, Virizuela J, López R, Lázaro M, Albanell J
Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (mRCC): A phase II study of sorafenib, gemcitabine (Gem), and metronomic capecitabine (Cap) in patients with advanced mRCC (SOGUG-02-06). J Clin Oncol. 2009 May 20; 27(15_suppl):5040.
Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (mRCC): A phase II study of sorafenib, gemcitabine (Gem), and metronomic capecitabine (Cap) in patients with advanced mRCC (SOGUG-02-06).
Rosenberg JE, Werner L, Selvarajah S, Weir B, Regan MM, Jacobus SJ, Berman DM, Schutz FA, O'Brien R, Choueiri TK, Barretina J, Signoretti S, Loda M, Guancial EA, Gallardo E, Rojo FG, Lloreta J, Hahn WC, Kantoff PW, Bellmunt J
Identification of a novel urothelial carcinoma (UC) biomarker of lethality. J Clin Oncol. 2011 May 20; 29(15_suppl):4569.
Identification of a novel urothelial carcinoma (UC) biomarker of lethality.
Bellmunt J, Knobel H, Navarro M, Jolis L
Nailfold capillary microscopy and bleomycin-induced vascular toxicity. Cancer Invest. 1990; 8(6):641.
Nailfold capillary microscopy and bleomycin-induced vascular toxicity.
Vogelzang NJ, Fizazi K, Burke JM, De Wit R, Bellmunt J, Hutson TE, Crane E, Berry WR, Doner K, Hainsworth JD, Wiechno PJ, Liu K, Waldman MF, Gandhi A, Barton D, Jungnelius U, Fandi A, Sternberg CN, Petrylak DP
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2017 02; 71(2):168-171.
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, Gonzalez Del Alba A, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Rodriguez de Antona C
Polymorphisms as markers of sunitinib efficacy and toxicity in first-line treatment of renal clear cell carcinoma: Final results of a multicentric prospective study by the Spanish Oncology Genitourinary Group. J Clin Oncol. 2011 May 20; 29(15_suppl):4559.
Polymorphisms as markers of sunitinib efficacy and toxicity in first-line treatment of renal clear cell carcinoma: Final results of a multicentric prospective study by the Spanish Oncology Genitourinary Group.
Montagut C, Arriola E, Galvan AB, Rojo FG, Salido M, Gallen M, Garcia M, Martinez A, Pons F, Servitja S, Iglesias M, Menendez S, Serrano S, Sole F, Rovira A, Albanell J, Bellmunt J
ALK chromosomal alterations in neuroendocrine tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):10585.
ALK chromosomal alterations in neuroendocrine tumors.
Font A, Esteban E, Carles J, Climent MA, Gonzalez-Larriba JL, Berrocal A, Bellmunt J, Garcia-Ribas I, Marfa X, Fabregat X
Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4544.
Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
Melichar B, Bracarda S, Matveev V, Rusakov I, Kaprin A, Zyryanov A, Janciauskiene R, Fernebro E, Mickisch GH, Gore ME, Schulze A, Jethwa S, Sneller V, Mulders P, Bellmunt J
BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-a2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2011 May 20; 29(15_suppl):4546.
BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-a2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC).
Krajewski KM, Fougeray R, Choueiri TK, Pons F, Schutz FA, Rosenberg JE, Salhi Y, Bellmunt J
Optimization of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. J Clin Oncol. 2011 May 20; 29(15_suppl):4570.
Optimization of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.
Nunez I, Suarez C, Morales R, Gallén M, Planas J, Maldonado X, Valverde CM, Serrano C, Morote J, Bellmunt J, Carles J
Relationship of duration of androgen blockade and response to antiandrogen withdrawal: A retrospective study. J Clin Oncol. 2011 May 20; 29(15_suppl):e15104.
Relationship of duration of androgen blockade and response to antiandrogen withdrawal: A retrospective study.
Rojo F, Iglesias C, Tabernero J, Jimenez J, Rodriguez S, Bellmunt J, Ramon S, Baselga J
Molecular markers of the mTOR pathway activation in human tumors: A baseline analysis. J Clin Oncol. 2004 Jul 15; 22(14_suppl):9524.
Molecular markers of the mTOR pathway activation in human tumors: A baseline analysis.
Bellmunt J, De Gracia J, Morales S, Orriols R, Tallada N
Cytologic diagnosis in bronchoalveolar lavage specimens. A diagnostic technique for lung neoplasmas with a peripheral location. Chest. 1990 Aug; 98(2):513-4.
Cytologic diagnosis in bronchoalveolar lavage specimens. A diagnostic technique for lung neoplasmas with a peripheral location.
Bellmunt J, Selvarajah S, Rodig S, Salido M, Costa I, Bellosillo B, Werner L, Namgyal C, Schutz FA, Pons F, O'Brien R, Barretina J, Signoretti S, Loda M, Albanell J, Choueiri TK, Berman DM, Kantoff PW, Rosenberg JE
Identification of ALK gene alterations in urothelial carcinoma (UC). J Clin Oncol. 2011 May 20; 29(15_suppl):4568.
Identification of ALK gene alterations in urothelial carcinoma (UC).
Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. J Clin Oncol. 2011 May 20; 29(15_suppl):e15027.
Suarez C, Gallardo E, Rodon Ahnert J, Guix M, Bonfill T, Pons F, Beltran M, Moya I, Galtes S, Albanell J, Carles J, Bellmunt J
Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma. J Clin Oncol. 2011 May 20; 29(15_suppl):e15095.
Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma.
Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016 Apr 27; 2(2):165-202.
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.
Morales S, Navarro M, Bellmunt J, Jolis L
[Acromegaly and lung cancer]. Rev Clin Esp. 1989 Apr; 184(6):337-8.
de Morrée ES, Vogelzang NJ, Petrylak DP, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, Ochoa de Olza M, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, Li JS, de Wit R
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study. JAMA Oncol. 2017 Jan 01; 3(1):68-75.
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
Seisen T, Krasnow RE, Bellmunt J, Rouprêt M, Leow JJ, Lipsitz SR, Vetterlein MW, Preston MA, Hanna N, Kibel AS, Sun M, Choueiri TK, Trinh QD, Chang SL
Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol. 2017 Mar 10; 35(8):852-860.
Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma.
Rose TL, Deal AM, Ladoire S, Créhange G, Galsky MD, Rosenberg JE, Bellmunt J, Wimalasingham A, Wong YN, Harshman LC, Chowdhury S, Niegisch G, Liontos M, Yu EY, Pal SK, Chen RC, Wang AZ, Nielsen ME, Smith AB, Milowsky MI
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer. Bladder Cancer. 2016 Oct 27; 2(4):405-413.
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.
Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, Juco J, Lunceford J, Saraf S, Perini RF, O'Donnell PH
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017 Feb; 18(2):212-220.
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I
Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treat Rev. 2017 Feb; 53:79-97.
Strategies to design clinical studies to identify predictive biomarkers in cancer research.
Fossati N, Willemse PM, Van den Broeck T, van den Bergh RCN, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford P, De Santis M, MacPepple E, Henry AM, Mason MD, Matveev VB, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Lam TB, Mottet N, Joniau S
The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol. 2017 07; 72(1):84-109.
The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.
Necchi A, Pond GR, Raggi D, Giannatempo P, Vogelzang NJ, Grivas P, Galsky MD, Bellmunt J, Sonpavde G
Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2017 02; 15(1):23-30.e2.
Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Martin Liberal J, Maroto JP, Mellado B, Ferrer F, Sancho G, Rovirosa A, Vigues F, Palou J, Ribal MJ, Bellmunt J, Garcia Del Muro X
Phase I trial of sorafenib with concurrent radiotherapy (RT) in patients with invasive bladder cancer treated with bladder-sparing intent: A Spanish Oncology Genitourinary Group study. J Clin Oncol. 2012 Feb 10; 30(5_suppl):270.
Phase I trial of sorafenib with concurrent radiotherapy (RT) in patients with invasive bladder cancer treated with bladder-sparing intent: A Spanish Oncology Genitourinary Group study.
Werner L, Bellmunt J, Nikitas N, Stack EC, Lis R, Signoretti S, Loda M, Regan MM, Park RS, O'Brien R, Berman DM, Bamias A, Rosenberg JE
Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):260.
Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC).
Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev V, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, De Bono JS, Paliwal P, Durham S, Cheng S, Logothetis C
Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. J Clin Oncol. 2013 Feb 20; 31(6_suppl):LBA8.
Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.
Guancial EA, Werner L, Stack E, Lis R, Signoretti S, Loda M, Gallardo E, Rojo F, Lloreta J, Regan MM, Park R, O'Brien R, Berman DM, Bellmunt J, Rosenberg JE
Association of DNA repair factors with overall survival in advanced urothelial carcinoma treated with platinum-based chemotherapy. J Clin Oncol. 2012 Feb 10; 30(5_suppl):291.
Association of DNA repair factors with overall survival in advanced urothelial carcinoma treated with platinum-based chemotherapy.
Iyer G, Riester M, Werner L, Schultz N, Stack EC, Park R, Loda M, Ostrovnaya I, Kantoff PW, Bajorin DF, Solit DB, Michor F, Bellmunt J, Rosenberg JE
Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):279.
Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC).
Agarwal N, Bellmunt J, Choueiri TK, Qu AQ, Fougeray R, Niegisch G, Galsky MD, Wong YN, Stadler WM, Sridhar SS, Sternberg CN, Sonpavde G
Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):301.
Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC).
Riester M, Bellmunt J, Stack EC, Werner L, Park R, Iyer G, Loda M, Kantoff PW, Michor F, Rosenberg JE
Genomic characterization of metastatic urothelial carcinoma. J Clin Oncol. 2013 Feb 20; 31(6_suppl):247.
Genomic characterization of metastatic urothelial carcinoma.
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clin Cancer Res. 2017 Jul 15; 23(14):3610-3618.
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.
Duran I, Montagut C, Calvo E, Galtes S, Navarrete A, Rodriguez-Pascual J, Hidalgo M, Rodriguez-Moreno JF, Cubillo A, Garcia A, Sanchez L, Barbas C, Viqueira A, Bellmunt J
Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel. J Clin Oncol. 2012 Feb 10; 30(5_suppl):250.
Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel.
Ramos JD, Casey MF, Bamias A, De Giorgi U, Bellmunt J, Harshman LC, Ladoire S, Wong YN, Alva AS, Rosenberg JE, Galsky MD, Yu EY
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. Clin Appl Thromb Hemost. 2017 Oct; 23(7):755-760.
The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treat Rev. 2017 Mar; 54:58-67.
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist. 2017 03; 22(3):286-292.
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
Ribas A, Albanell J, Bellmunt J, Solé-Calvo LA
Journal of the National Cancer Institute
Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst. 1997 Mar 05; 89(5):395-6.
Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
Bellmunt J, Morales S, Albanell J, Gallego O
Nail-fold capillary microscopy and chemotherapy-induced vascular toxicity. Ann Oncol. 1991 Apr; 2(4):310.
Nail-fold capillary microscopy and chemotherapy-induced vascular toxicity.
Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol. 2003 Jun 27; 46 Suppl:S85-104.
Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
Salud A, Porcel JM, Vidal-Pla R, Bellmunt J
[Pulmonary metastasising benign leiomyoma evolving to chronic respiratory failure]. Med Clin (Barc). 1997 Sep 20; 109(9):358.
[Pulmonary metastasising benign leiomyoma evolving to chronic respiratory failure].
Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998 Feb; 16(2):453-61.
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Albanell J, Tabernero JM, Cortés-Funes H, Baselga J
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. Eur J Cancer. 2000 Jul; 36 Suppl 2:17-25.
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
Bellmunt J, Albanell J, Gallego OS, Vicente P
[Antineoplastic chemotherapy in digestive tumors]. Med Clin (Barc). 1991 Sep 21; 97(9):358.
[Antineoplastic chemotherapy in digestive tumors].
Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017 04; 71(4):630-642.
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 04; 71(4):618-629.
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Gakis G, Schubert T, Alemozaffar M, Bellmunt J, Bochner BH, Boorjian SA, Daneshmand S, Huang WC, Kondo T, Konety BR, Laguna MP, Matin SF, Siefker-Radtke AO, Shariat SF, Stenzl A
Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World J Urol. 2017 Mar; 35(3):327-335.
Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease.
Bellmunt J, Trigo JM, Garcia-Ribas I, Roca JM, Galtes S, Perez-Romero A, de la Cruz JJ, Tabernero JM, Alba E, Baselga J
Phase I study of high-dose bi-weekly gemcitabine at a constant rate infusion (CRI) without growth factor support in advanced solid tumors, including prior standard gemcitabine treated patients. J Clin Oncol. 2005 Jun; 23(16_suppl):2067.
Phase I study of high-dose bi-weekly gemcitabine at a constant rate infusion (CRI) without growth factor support in advanced solid tumors, including prior standard gemcitabine treated patients.
de Bono JS, Bellmunt J, Droz JP, Miller K, Zugmaier G, Sternberg C, Gimenez V, Parker C, Mason M, Graham J
An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC). J Clin Oncol. 2005 Jun; 23(16_suppl):4609.
An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC).
De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res. 2017 04; 5(4):312-318.
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 03 16; 376(11):1015-1026.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Vicente P, Rovirosa A, Gallego O, Albanell J, Bellmunt J, Solé LA
Anales de medicina interna (Madrid, Spain : 1984)
[Spinal cord compression as a primary manifestation of occult thyroid carcinoma]. An Med Interna. 1992 Jul; 9(7):334-6.
[Spinal cord compression as a primary manifestation of occult thyroid carcinoma].
Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors. Semin Oncol. 2008 Jun; 35(3 Suppl 3):S34-43.
Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
Bellmunt J, Albiol S, Suárez C, Albanell J
Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol. 2009 Mar; 69(3):211-22.
Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents.
Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O
What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol. 2017 08; 72(2):250-266.
What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
Bellmunt J, Albanell J, Gallego OS, Ribas A, Vicente P, Carulla J, De Torres J, Morote J, Lopez M, Solé LA
Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer. 1992 Oct 01; 70(7):1974-9.
Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy.
García-Donas J, Font A, Pérez-Valderrama B, Virizuela JA, Climent MÁ, Hernando-Polo S, Arranz JÁ, Del Mar Llorente M, Lainez N, Villa-Guzmán JC, Mellado B, González Del Alba A, Castellano D, Gallardo E, Anido U, García Del Muro X, Domènech M, Puente J, Morales-Barrera R, Pérez-Gracia JL, Bellmunt J
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. Lancet Oncol. 2017 05; 18(5):672-681a.
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
Ribas A, Albanell J, Bellmunt J, Bermejo B, Gallardo E, Vera R, Bodi R, Solé-Calvo LA
Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule. Acta Oncol. 1997; 36(7):701-4.
Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule.
Navarro M, Mur E, Jolis L, Bellmunt J, Bodi R, Solé LA, Rubio D
[Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung]. Rev Clin Esp. 1991 Oct; 189(5):209-12.
[Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung].
Seisen T, Sun M, Lipsitz SR, Abdollah F, Leow JJ, Menon M, Preston MA, Harshman LC, Kibel AS, Nguyen PL, Bellmunt J, Choueiri TK, Trinh QD
Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017 10; 72(4):483-487.
Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.
Bellmunt J, Kerst JM, Vázquez F, Morales-Barrera R, Grande E, Medina A, González Graguera MB, Rubio G, Anido U, Fernández Calvo O, González-Billalabeitia E, Van den Eertwegh AJM, Pujol E, Perez-Gracia JL, González Larriba JL, Collado R, Los M, Maciá S, De Wit R
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). Ann Oncol. 2017 Jul 01; 28(7):1517-1522.
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).
Albanell J, Gallego OS, Bellmunt J, Vicente P, Morales S, Solé LA
[Bladder neoplasm in a patient with panarteritis nodosa treated with cyclophosphamide]. Rev Clin Esp. 1992 May; 190(9):463-5.
[Bladder neoplasm in a patient with panarteritis nodosa treated with cyclophosphamide].
Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B, Solé LA, Baselga J
Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 1997 Nov 15; 80(10):1966-72.
Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
Rovirosa Casino A, Bellmunt J, Salud A, Vicente P, Maldonado J, Bodi R, Salvador L
Endobronchial metastases in colorectal adenocarcinoma. Tumori. 1992 Aug 31; 78(4):270-3.
Endobronchial metastases in colorectal adenocarcinoma.
Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A, Anderson S, Bukowski R, Eisen T, Escudier B
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer. 2010 Sep; 46(13):2432-40.
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
Bellmunt J, Choueiri TK, Schutz FA, Rosenberg JE
Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls. Ann Oncol. 2011 Feb; 22(2):245-7.
Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls.
Castellano D, Carles J, Esteban E, Trigo JM, Climent MÁ, Maroto JP, del Muro XG, Font A, Paz-Ares L, Arranz JÁ, Bellmunt J
Recommendations for the optimal management of early and advanced urothelial carcinoma. Cancer Treat Rev. 2012 Aug; 38(5):431-41.
Recommendations for the optimal management of early and advanced urothelial carcinoma.
Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri S, Somasekar S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012 Jan 22; 18(2):221-3.
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013 Jan; 63(1):58-66.
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
Bone alkaline phosphatase serum level predicts the response to antiandrogen withdrawal. Eur Urol. 2002 Mar; 41(3):257-61.
Bone alkaline phosphatase serum level predicts the response to antiandrogen withdrawal.
Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R, Baselga J
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007 Mar; 18(3):522-8.
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Batiste-Alentorn E, Sáenz A, López-Brea M, Font A, Nogué M, Bastús R, Climent MA, de la Cruz JJ, Albanell J, Banús JM, Gallardo E, Diaz-Rubio E, Cortés-Funes H, Baselga J
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol. 2000 Sep 15; 18(18):3247-55.
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Bellmunt J, de Wit R, Albanell J, Baselga J
A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer. 2001 Nov; 37(17):2212-5.
A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer.
[The clinical importance of the fibroblast growth factor (bFGF) as a biological marker and therapeutic modulator. Future applications]. Med Clin (Barc). 1996 Sep 14; 107(8):296-8.
[The clinical importance of the fibroblast growth factor (bFGF) as a biological marker and therapeutic modulator. Future applications].
Bellmunt J, Albanell J, Salud A, Español T, Morales S, Solé-Calvo LA
Interferon and disseminated Langerhans cell histiocytosis. Med Pediatr Oncol. 1992; 20(4):336-7.
Interferon and disseminated Langerhans cell histiocytosis.
Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives. Drugs. 2017 Jul; 77(10):1077-1089.
Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Necchi A, Raggi D, Giannatempo P, Sonpavde G, Galsky MD, Bellmunt J, Mariani L, Miceli R
From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. Clin Genitourin Cancer. 2017 10; 15(5):509-512.e9.
From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis.
Wankowicz SAM, Werner L, Orsola A, Novak J, Bowden M, Choueiri TK, de Torres I, Morote J, Freeman GJ, Signoretti S, Bellmunt J
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. J Urol. 2017 10; 198(4):817-823.
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Fonteyne V, Ost P, Bellmunt J, Droz JP, Mongiat-Artus P, Inman B, Paillaud E, Saad F, Ploussard G
Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. Eur Urol. 2018 01; 73(1):40-50.
Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
Bellmunt J, Cos J, Clèries R, Pérez M, Ribas A, Eres N, Murio JE, Margarit C, Baselga J
Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest. 2002; 20(5-6):673-85.
Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer.
Margarit C, Escartín A, Bellmunt J, Allende E, Bilbao I
[Peripheral cholangiocarcinoma: results of surgical treatment]. Gastroenterol Hepatol. 2006 Apr; 29(4):215-23.
[Peripheral cholangiocarcinoma: results of surgical treatment].
Bellmunt J, Navarro M, Morales S, Jolis L, Carulla J, Knobell H, Vilardell M, Sole LA
Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity. Cancer. 1990 Jan 15; 65(2):303-9.
Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity.
Bellmunt J, Eres N, Ribas A, Casado S, Albanell J, Baselga J
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. Cancer Chemother Pharmacol. 1997; 40(3):273-6.
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
Anderson J, Van Poppel H, Bellmunt J, Miller K, Droz JP, Fitzpatrick JM
Chemotherapy for older patients with prostate cancer. BJU Int. 2007 Feb; 99(2):269-73.
Chemotherapy for older patients with prostate cancer.
Pembrolizumab for Advanced Urothelial Carcinoma. N Engl J Med. 2017 06 08; 376(23):2304.
Pembrolizumab for Advanced Urothelial Carcinoma.
Sternberg CN, Krainer M, Oh WK, Bracarda S, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, Fitzpatrick JM
The medical management of prostate cancer: a multidisciplinary team approach. BJU Int. 2007 Jan; 99(1):22-7.
The medical management of prostate cancer: a multidisciplinary team approach.
Navarro M, Felip E, Garcia L, Bellmunt J, Jolis L, Morales S, Rubio D
Addison's disease secondary to prostatic carcinoma. A case report. Tumori. 1990 Dec 31; 76(6):611-3.
Addison's disease secondary to prostatic carcinoma. A case report.
de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol. 2007 Jan 20; 25(3):257-62.
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
Sunitinib in renal-cell carcinoma: expanded indications. Lancet Oncol. 2009 Aug; 10(8):740.
Sunitinib in renal-cell carcinoma: expanded indications.
Bellmunt J, de Wit R, Albiol S, Tabernero J, Albanell J, Baselga J
New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol. 2003 Aug; 47(2):195-206.
New drugs and new approaches in metastatic bladder cancer.
Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, Sternberg CN, Sonpavde G
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012 Sep; 62(3):523-33.
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M
EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. 2009 Mar; 45(5):765-73.
EORTC-GU group expert opinion on metastatic renal cell cancer.
[New cell target treatments: indications, results and tolerance]. Actas Urol Esp. 2009 May; 33(5):609-14.
[New cell target treatments: indications, results and tolerance].
European early phase II dose-finding study of droloxifene in advanced breast cancer. Am J Clin Oncol. 1991; 14 Suppl 2:S36-9.
European early phase II dose-finding study of droloxifene in advanced breast cancer.
Ramírez de Olano A, Bellmunt J, Rodrigo A, Álvarez L, Terrádez A, García-Foncillas J, Laes JF
A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma. Case Rep Oncol. 2017 May-Aug; 10(2):493-500.
A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma.
Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20; 27(27):4454-61.
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.
Ribas A, Bellmunt J, Solé LA, Ribas-Mundó M
[Corticoid treatment in Castleman's disease]. Med Clin (Barc). 1995 Nov 11; 105(16):638-9.
[Corticoid treatment in Castleman's disease].
Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies. BJU Int. 2012 Mar; 109 Suppl 2:14-9.
Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies.
The optimize project: beyond first-line therapy in metastatic renal cell carcinoma. Cancer Metastasis Rev. 2012 Sep; 31 Suppl 1:S1-2.
The optimize project: beyond first-line therapy in metastatic renal cell carcinoma.
Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol. 2009 Jun; 55(6):1310-2.
Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail?
Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F, Buonerba C
Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 2011 Apr; 59(4):526-40.
Toxicities of targeted therapy and their management in kidney cancer.
Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011 Apr; 59(4):572-83.
Martin-Broto J, Gutierrez A, Garcia-Del-Muro X, Lopez-Guerrero JA, Martinez-Trufero J, de Sande LM, Lainez N, Maurel J, De Juan A, Losa F, Andres R, Casado A, Tejido PG, Blanco R, Carles J, Bellmunt J, Gomez-España A, Ramos R, Martinez-Serra J, Llombart-Bosch A, Poveda A
Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol. 2010 Jul; 21(7):1552-1557.
Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study.
Krajewski KM, Fougeray R, Bellmunt J, Pons F, Schutz FA, Rosenberg JE, Salhi Y, Choueiri TK
Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer. 2012 Jul; 48(10):1495-502.
Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.
Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA, Abraham P, Rosenberg JE
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017; 5:68.
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
Seisen T, Jamzadeh A, Leow JJ, Rouprêt M, Cole AP, Lipsitz SR, Kibel AS, Nguyen PL, Sun M, Menon M, Bellmunt J, Choueiri TK, Trinh QD
Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol. 2018 Feb 01; 4(2):225-229.
Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy.
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 08 15; 5(1):68.
Kamat AM, Lerner S, Black P, Bellmunt J, Dinney C, Hahn NM, O'Donnell M, Quale DZ
Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. Bladder Cancer. 2017 Jul 27; 3(3):145-146.
Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.
Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, Cornford P, Cumberbatch MG, Fossati N, Gross T, Henry AM, Bolla M, Briers E, Joniau S, Lam TB, Mason MD, Mottet N, van der Poel HG, Rouvière O, Schoots IG, Wiegel T, Willemse PM, Yuan CY, Bourke L
Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. Eur Urol. 2017 12; 72(6):869-885.
Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.
Leow JJ, Cole AP, Seisen T, Bellmunt J, Mossanen M, Menon M, Preston MA, Choueiri TK, Kibel AS, Chung BI, Sun M, Chang SL, Trinh QD
Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. Eur Urol. 2018 Mar; 73(3):374-382.
Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA.
Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC, Chowdhury S, Niegisch G, Yu EY, Pal SK, De Giorgi U, Crabb SJ, Caubet M, Balssa L, Milowsky MI, Ladoire S, Créhange G
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Acta Oncol. 2018 Apr; 57(4):491-497.
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure Á, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol. 2010 Feb; 21(2):195-198.
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).
Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010 May 01; 28(13):2144-50.
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
Bellmunt J, Orsola A, Maldonado X, Kataja V
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May; 21 Suppl 5:v134-6.
¹¹C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy. BJU Int. 2010 Nov; 106(9):1249-50.
¹¹C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy.
Variant forms of bladder cancer: basic considerations on treatment approaches. Curr Oncol Rep. 2011 Jun; 13(3):216-21.
Variant forms of bladder cancer: basic considerations on treatment approaches.
Sevillano E, Werner L, Bossé D, Lalani AA, Wankowicz SAM, de Velasco G, Farina M, Lundgren K, Choueiri TK, González Del Alba A, Bellmunt J
Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis. Clin Genitourin Cancer. 2017 12; 15(6):e1089-e1094.
Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis.
Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open. 2016; 1(6):e000126.
Upper tract urothelial carcinoma: a different disease entity in terms of management.
Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2012 May; 23(5):1234-1240.
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.
Vetterlein MW, Seisen T, Leow JJ, Preston MA, Sun M, Friedlander DF, Meyer CP, Chun FK, Lipsitz SR, Menon M, Kibel AS, Bellmunt J, Choueiri TK, Trinh QD
Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clin Genitourin Cancer. 2017 Aug 24.
Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer.
Antiangiogenesis to curb urothelial cancer. Lancet. 2017 11 18; 390(10109):2220-2221.
Antiangiogenesis to curb urothelial cancer.
Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, De Giorgi U, Hussain S, Alva AS, Baniel J, Agarwal N, Rosenberg JE, Vaishampayan UN, Galsky MD, Yu EY
Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. Clin Genitourin Cancer. 2017 Aug 24.
Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors.
'Working toward understanding oligo and polymetastatic prostate cancer'. Curr Opin Urol. 2017 11; 27(6):532.
'Working toward understanding oligo and polymetastatic prostate cancer'.
Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol. 2008 Aug; 19(8):1387-1392.
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.
Bellmunt J, Macià F, Malmusi D, Llorente JA, Carles J, Lloreta J, Foro P, Gelabert A, Albanell J, Castells X
Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients. Eur J Cancer. 2009 Nov; 45(16):2804-9.
Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients.
Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010 Apr 10; 28(11):1850-5.
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
Schutz FA, Bellmunt J, Rosenberg JE, Choueiri TK
Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid. Expert Opin Drug Saf. 2011 Jul; 10(4):645-53.
Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.
Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Actas Urol Esp. 2011 Nov-Dec; 35(10):565-79.
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Bellmunt J, Attard G, Bahl A, Huland H, Klotz L, Kuban D, Oudard S, Watson W
Advances in the management of high-risk localised and metastatic prostate cancer. BJU Int. 2012 Mar; 109 Suppl 2:8-13.
Advances in the management of high-risk localised and metastatic prostate cancer.
Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 09 28; 5(1):80.
Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
Bellmunt J, Eigl BJ, Senkus E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar SS, Sternberg CN, Retz M, Pal S, Blumenstein B, Jacobs C, Stewart PS, Petrylak DP
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. Ann Oncol. 2017 Oct 01; 28(10):2481-2488.
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. Eur Urol Focus. 2018 12; 4(6):937-945.
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 11; 18(11):1483-1492.
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Bellmunt J, Albanell J, Paz-Ares L, Climent MA, González-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Díaz-Rubio E, Cortés-Funes H, Baselga J
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer. 2002 Aug 15; 95(4):751-7.
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19; 171(3):540-556.e25.
Hurtado A, Pinós T, Barbosa-Desongles A, López-Avilés S, Barquinero J, Petriz J, Santamaria-Martínez A, Morote J, de Torres I, Bellmunt J, Reventós J, Munell F
Cellular oncology : the official journal of the International Society for Cellular Oncology
Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a non-genomic mechanism in prostate carcinoma cells. Cell Oncol. 2008; 30(4):349-65.
Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a non-genomic mechanism in prostate carcinoma cells.
Predictive modelling in hormone-refractory prostate cancer (HRPC). Clin Transl Oncol. 2009 Feb; 11(2):82-5.
Predictive modelling in hormone-refractory prostate cancer (HRPC).
Dutcher JP, Tannir N, Bellmunt J, Escudier B
Experience with sorafenib and the elderly patient. Med Oncol. 2010 Dec; 27(4):1359-70.
Experience with sorafenib and the elderly patient.
Fizazi K, Ulys A, Sengeløv L, Moe M, Ladoire S, Thiery-Vuillemin A, Flechon A, Guida A, Bellmunt J, Climent MA, Chowdhury S, Dumez H, Matouskova M, Penel N, Liutkauskiene S, Stachurski L, Sternberg CN, Baton F, Germann N, Daugaard G
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. Ann Oncol. 2017 Nov 01; 28(11):2741-2746.
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.
Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Ann Oncol. 2018 02 01; 29(2):361-369.
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Albanell J, Salud A, Bellmunt J, Español T, Morales S, García-Bragado F, Solé-Calvo LA
[Treatment with interferon of systemic Langerhans-cell histiocytosis in an adult]. Med Clin (Barc). 1990 Feb 10; 94(5):184-6.
[Treatment with interferon of systemic Langerhans-cell histiocytosis in an adult].
Bellmunt J, Eisen T, Szczylik C, Mulders P, Porta C
A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU Int. 2011 Apr; 107(8):1190-9.
A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V
Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep; 22 Suppl 6:vi45-9.
Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S
Current vaccination strategies for prostate cancer. Eur Urol. 2012 Feb; 61(2):290-306.
Current vaccination strategies for prostate cancer.
Morales-Barrera R, Bellmunt J, Suárez C, Valverde C, Guix M, Serrano C, Gallén M, Carles J
Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer. 2012 Aug; 48(12):1816-21.
Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.
Rescigno P, Buonerba C, Bellmunt J, Sonpavde G, De Placido S, Di Lorenzo G
New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets. 2012 Dec; 13(13):1676-86.
New perspectives in the therapy of castration resistant prostate cancer.
Vetterlein MW, Wankowicz SAM, Seisen T, Lander R, Löppenberg B, Chun FK, Menon M, Sun M, Barletta JA, Choueiri TK, Bellmunt J, Trinh QD, Preston MA
Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer. 2017 Nov 15; 123(22):4346-4355.
Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review. Cancer Treat Rev. 2017 Dec; 61:82-93.
The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review.
Chemotherapy for metastatic or unresectable bladder cancer. Semin Oncol. 2007 Apr; 34(2):135-44.
Chemotherapy for metastatic or unresectable bladder cancer.
Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco G, Maluf FC, Fay AP, Bellmunt J, Choueiri TK, Schutz FA
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget. 2017 Oct 13; 8(48):84572-84578.
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.
Bellmunt J, Morales S, Navarro M, Solé LA
Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines. Cancer Chemother Pharmacol. 1990; 26 Suppl:S81-4.
Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines.
[Advanced bladder cancer: new therapeutic strategies]. Med Clin (Barc). 2003 Jan 25; 120(2):68-77.
[Advanced bladder cancer: new therapeutic strategies].
Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010 May 01; 28(13):2280-5.
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Overview of gemcitabine triplets in metastatic bladder cancer. Crit Rev Oncol Hematol. 2003 Feb; 45(2):191-7.
Overview of gemcitabine triplets in metastatic bladder cancer.
Vilà MR, Kaplan GG, Feigelstock D, Nadal M, Morote J, Porta R, Bellmunt J, Meseguer A
Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma. Kidney Int. 2004 May; 65(5):1761-73.
Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma.
Moschini M, Shariat SF, Rouprêt M, De Santis M, Bellmunt J, Sternberg CN, Tombal B, Collette L
Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies. J Urol. 2018 05; 199(5):1149-1157.
Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD
Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clin Genitourin Cancer. 2018 04; 16(2):e483-e490.
Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.
Paz-Ares L, López-Pousa A, Poveda A, Balañá C, Ciruelos E, Bellmunt J, del Muro JG, Provencio M, Casado A, Rivera-Herrero F, Izquierdo MA, Nieto A, Tanovic A, Cortes-Funes H, Buesa JM
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs. 2012 Apr; 30(2):729-40.
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.
Bellmunt J, González-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011 Dec; 22(12):2646-2653.
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
[EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]. Actas Urol Esp. 2011 Oct; 35(9):501-14.
[EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease].
What are the expected developments in the medical treatment of bladder cancer. Eur J Cancer. 2011 Sep; 47 Suppl 3:S294-7.
What are the expected developments in the medical treatment of bladder cancer.
Tabernero J, Rojo F, Marimón I, Voi M, Albanell J, Guix M, Vázquez F, Carulla J, Cooper M, Andreu J, Van Vreckem A, Bellmunt J, Manne V, Manning JA, Garrido C, Felip E, Del Campo JM, García M, Valverde S, Baselga J
Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2005 Apr 10; 23(11):2521-33.
Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.
De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012 Jan 10; 30(2):191-9.
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.
Bellmunt J, Albiol S, de Olano AR, Pujadas J, Maroto P
Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Ann Oncol. 2006 May; 17 Suppl 5:v113-7.
Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.
Bellmunt J, Négrier S, Escudier B, Awada A, Aapro M
The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol. 2009 Jan; 69(1):64-72.
The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce.
[Glycoprotein P and resistance to antitumor chemotherapy]. Med Clin (Barc). 1993 Dec 11; 101(20):785-8.
[Glycoprotein P and resistance to antitumor chemotherapy].
Bellmunt J, Ribas A, Ocaña I, Capdevila JA, Ruiz-Marcellan MC, Giralt J, Sole LA
[Initial clinicopathological manifestations of malignant lymphoproliferative processes in patients with human immunodeficiency virus seropositivity. Study of 40 cases]. An Med Interna. 1994 May; 11(5):217-23.
[Initial clinicopathological manifestations of malignant lymphoproliferative processes in patients with human immunodeficiency virus seropositivity. Study of 40 cases].
[Current strategies in the treatment of renal-cell cancer: targeted therapies]. Med Clin (Barc). 2008 Mar 22; 130(10):380-92.
[Current strategies in the treatment of renal-cell cancer: targeted therapies].
Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008 May; 19 Suppl 2:ii47-8.
Pembrolizumab in the treatment of advanced urothelial cancer. Future Oncol. 2017 Dec; 13(30):2745-2758.
Pembrolizumab in the treatment of advanced urothelial cancer.
Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, Weiner-Taylor A, Wankowicz S, Han G, Teo MY, Cipolla C, Kim J, Iyer G, Al-Ahmadie H, Dulaimi E, Chen DYT, Alpaugh RK, Hoffman-Censits J, Garraway LA, Getz G, Carter SL, Bellmunt J, Plimack ER, Rosenberg JE, Van Allen EM
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017 12 19; 8(1):2193.
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.
Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K
Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. Eur Urol Focus. 2019 03; 5(2):242-249.
Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.
Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma. Nat Rev Clin Oncol. 2018 02; 15(2):73-74.
Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma.
Urun Y, Leow JJ, Fay AP, Albiges L, Choueiri TK, Bellmunt J
ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Dec; 120:120-126.
ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis.
Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. Eur Urol. 2009 Oct; 56(4):606-8.
Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer.
Escudier B, Osanto S, Ljungberg B, Porta C, Wagstaff J, Mulders P, Gore M, Bex A, Bellmunt J, Bracarda S, Franklin A, Honoré PH, Ravaud A, Steijn Jv, Aziz Z, Akaza H
Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treat Rev. 2012 Apr; 38(2):127-32.
Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies.
Hanna N, Leow JJ, Sun M, Friedlander DF, Seisen T, Abdollah F, Lipsitz SR, Menon M, Kibel AS, Bellmunt J, Choueiri TK, Trinh QD
Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urol Oncol. 2018 03; 36(3):88.e1-88.e9.
Comparative effectiveness of robot-assisted vs. open radical cystectomy.
De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Skoneczna I, Marreaud S, de Wit R, Sylvester R
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol. 2009 Nov 20; 27(33):5634-9.
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P
Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev. 2010 Feb; 36(1):16-23.
Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma.
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. Cancer Metastasis Rev. 2010 Aug; 29 Suppl 1:11-20.
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations.
Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011 Mar; 12(3):211-4.
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.
Appleby L, Morrissey S, Bellmunt J, Rosenberg J
Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices. Hematol Oncol Clin North Am. 2011 Aug; 25(4):893-915.
Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.
Bellmunt J, Navarro M, Hidalgo R, Solé LA
Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. Tumori. 1988 Jun 30; 74(3):329-31.
Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil.
Bracarda S, Bellmunt J, Melichar B, Négrier S, Bajetta E, Ravaud A, Sneller V, Escudier B
Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-a2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int. 2011 Jan; 107(2):214-9.
Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-a2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
Pera M, Gallego R, Montagut C, Martín-Richard M, Iglesias M, Conill C, Reig A, Balagué C, Pétriz L, Momblan D, Bellmunt J, Maurel J
Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol. 2012 Mar; 23(3):664-670.
Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer.
Therapeutic advances in medical oncology
Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol. 2010 May; 2(3):189-207.
Castration-resistant prostate cancer: new science and therapeutic prospects.
Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, Choueiri TK
Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018 01 22; 6(1):5.
Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.
Navarro M, Bellmunt J, Balañá C, Colomer R, Jolis L, del Campo JM
Mitomycin-C and vinblastine in advanced breast cancer. Oncology. 1989; 46(3):137-42.
Mitomycin-C and vinblastine in advanced breast cancer.
Future developments in renal cell carcinoma. Ann Oncol. 2009 May; 20 Suppl 1:i13-17.
Future developments in renal cell carcinoma.
Montagut C, Iglesias M, Arumi M, Bellosillo B, Gallen M, Martinez-Fernandez A, Martinez-Aviles L, Cañadas I, Dalmases A, Moragon E, Lema L, Serrano S, Rovira A, Rojo F, Bellmunt J, Albanell J
Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. Br J Cancer. 2010 Mar 30; 102(7):1137-44.
Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. Med Oncol. 2011 Dec; 28(4):1379-83.
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
Rodriguez-Vida A, Hutson TE, Bellmunt J, Strijbos MH
New treatment options for metastatic renal cell carcinoma. ESMO Open. 2017; 2(2):e000185.
New treatment options for metastatic renal cell carcinoma.
[Regulatory proteins of the cell cycle: alterations in the cycline D1 pathway as a paradigm. Findings in breast cancer]. Med Clin (Barc). 1998 Nov 07; 111(15):592-6.
[Regulatory proteins of the cell cycle: alterations in the cycline D1 pathway as a paradigm. Findings in breast cancer].
New therapeutic challenges in advanced bladder cancer. Semin Oncol. 2012 Oct; 39(5):598-607.
New therapeutic challenges in advanced bladder cancer.